Date: 2015-04-08
Type of information: Capital increase
Company: Prothena (Ireland)
Investors:
Amount:
Funding type: capital increase
Planned used:
Others: * On April 8, 2015, Prothena, a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, announced that it priced an underwritten public offering of 3,300,000 of its ordinary shares at a price to the public of $37.00 per ordinary share, before the underwriting discount. All of the ordinary shares in the offering were sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 495,000 of its ordinary shares. Net proceeds to Prothena from the ordinary shares to be sold by Prothena in the offering are expected to be $114.2 million, after deducting the underwriting discount and estimated offering expenses, but excluding any exercise of the underwriters\' option to purchase additional ordinary shares. The offering is expected to close on April 13, 2015, subject to customary closing conditions. Credit Suisse, RBC Capital Markets and UBS Investment Bank are acting as joint book-running managers, and Oppenheimer & Co., Wedbush PacGrow, Ladenburg Thalmann and LifeSci Capital are acting as co-managers for the offering. * On April 6, 2015, Prothena announced that it has commenced an underwritten public offering of 3,300,000 of its ordinary shares. All of the ordinary shares in the offering will be sold by Prothena. In addition, Prothena has granted the underwriters a 30-day option to purchase up to an additional 495,000 of its ordinary shares. Credit Suisse and RBC Capital Markets are acting as joint book-running managers. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering will be completed, or as to the actual size or terms of the offering. The ordinary shares of Prothena described above are being offered only by means of a prospectus supplement and base prospectus forming part of an effective shelf registration statement filed with the Securities and Exchange Commission. Copies of the prospectus for this offering may be obtained, when available, by contacting Credit Suisse Securities.
Therapeutic area:
